All In Biotech

Drug Trial Radar · NCT06680440

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity

A Phase I Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASC30 Tablets in Participants With Obesity

Last checked: Nov 19, 2026Latest source record: May 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Aug 26, 2024

Primary completion

Apr 3, 2025

Study completion Apr 3, 2025

Sponsor

Sponsor type
Industry
First posted
Nov 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, efficacy, food effect of ASC30 Tablets or ASC30 Tablets A1 in participants with obesity.

Conditions

  • Weight Management

Interventions

  • ASC30Drug

    Tablet, QD

  • PlaceboOther

    Tablets, QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AEs, SAEs (Safety and Tolerability) of ASC30 (SAD)Time frame: Up to Day 8
  2. Incidence of AEs, SAEs (Safety and Tolerability) of ASC30 (MAD)Time frame: Up to Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ascletis clinical site

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.